Kingswood Wealth Advisors LLC purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 7,584 shares of the biopharmaceutical company’s stock, valued at approximately $228,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Oppenheimer & Co. Inc. bought a new stake in TG Therapeutics during the 3rd quarter worth approximately $759,000. Segall Bryant & Hamill LLC purchased a new position in shares of TG Therapeutics during the 3rd quarter valued at $1,225,000. Barclays PLC increased its holdings in shares of TG Therapeutics by 83.9% in the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock worth $8,117,000 after purchasing an additional 158,323 shares during the period. Principal Financial Group Inc. raised its position in shares of TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after buying an additional 725,371 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in TG Therapeutics by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after buying an additional 270,286 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.
TG Therapeutics Price Performance
Shares of TG Therapeutics stock opened at $31.70 on Friday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics, Inc. has a 52-week low of $12.84 and a 52-week high of $36.84. The company has a fifty day moving average of $31.63 and a 200-day moving average of $26.55. The stock has a market capitalization of $4.93 billion, a price-to-earnings ratio of -316.97 and a beta of 2.24.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on TGTX. JPMorgan Chase & Co. raised their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. StockNews.com lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Wednesday, January 15th. Finally, TD Cowen began coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.
View Our Latest Stock Report on TGTX
Insider Buying and Selling
In other news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the transaction, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,358 shares of company stock worth $781,497 in the last ninety days. 10.50% of the stock is owned by insiders.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Read More
- Five stocks we like better than TG Therapeutics
- How to Evaluate a Stock Before BuyingÂ
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- Learn Technical Analysis Skills to Master the Stock Market
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- Dividend Capture Strategy: What You Need to Know
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report).
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.